Holen Sie sich die Stockscreener-App
2.295
4.77%
-0.115
Schlusskurs vom Vortag:
$2.41
Offen:
$2.41
24-Stunden-Volumen:
260.92K
Relative Volume:
0.22
Marktkapitalisierung:
$217.27M
Einnahmen:
$26.87M
Nettoeinkommen (Verlust:
$-124.13M
KGV:
-1.3206
EPS:
-1.7378
Netto-Cashflow:
$-125.60M
1W Leistung:
+7.75%
1M Leistung:
-20.03%
6M Leistung:
-41.00%
1J Leistung:
+39.94%
1-Tages-Spanne:
$2.27
$2.41
1-Wochen-Bereich:
$2.07
$2.47
52-Wochen-Spanne:
$1.212
$6.95
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Firmenname
Zentalis Pharmaceuticals Inc
Sektor
Branche
Telefon
(858) 263-4333
Adresse
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Compare ZNTL vs VRTX, REGN, MRNA, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
2.295 | 217.27M | 26.87M | -124.13M | -125.60M | -1.7378 |
VRTX
Vertex Pharmaceuticals Inc
|
525.63 | 133.23B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
808.80 | 83.27B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
205.71 | 82.12B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
879.53 | 55.31B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
375.74 | 42.50B | 5.76B | 514.49M | 1.10B | 4.4813 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-05 | Fortgesetzt | Leerink Partners | Outperform |
| 2026-09-30 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2026-09-16 | Eingeleitet | William Blair | Outperform |
| 2026-07-23 | Eingeleitet | Rodman & Renshaw | Buy |
| 2026-07-17 | Eingeleitet | Mizuho | Outperform |
| 2026-03-17 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2024-08-12 | Hochstufung | Wedbush | Underperform → Neutral |
| 2024-06-20 | Herabstufung | UBS | Buy → Neutral |
| 2024-06-18 | Herabstufung | Jefferies | Buy → Hold |
| 2024-06-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-18 | Herabstufung | Wedbush | Neutral → Underperform |
| 2024-06-18 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-11-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-11-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2022-07-12 | Eingeleitet | Cowen | Outperform |
| 2022-04-06 | Eingeleitet | Wells Fargo | Overweight |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-29 | Eingeleitet | Oppenheimer | Outperform |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-01-20 | Eingeleitet | Wedbush | Outperform |
| 2020-09-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-08-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-28 | Eingeleitet | Guggenheim | Buy |
| 2020-04-28 | Eingeleitet | Jefferies | Buy |
| 2020-04-28 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-04-28 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Zentalis Pharmaceuticals Inc Aktie (ZNTL) Neueste Nachrichten
Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract - GlobeNewswire Inc.
ZNTL Stock Price, Quote & News - Syfe
Certain Stock Options of Zentalis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-OCT-2026. - marketscreener.com
Certain Common Stock of Zentalis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-OCT-2026. - www.marketscreener.com
Leerink Upgrades Zentalis Pharmaceuticals to Outperform From Market Perform, Price Target is $8 - Yahoo Finance
Form 4 Zentalis Pharmaceuticals Llc For: 1 October By Investing.com - Investing.com South Africa
Wells Fargo sets USD 5.00 target for Zentalis Pharmaceuticals stock - AD HOC NEWS
Form 4 Zentalis Pharmaceuticals Llc For: 1 October By Investing.com - Investing.com Nigeria
Form 4 Zentalis Pharmaceuticals Llc For: 1 October By Investing.com - Investing.com UK
At $2.18 a share, Ingmar Bruns acquires 9,727 shares in Zentalis Pharmaceuticals (ZNTL). - Stock Titan
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Zentalis Pharmaceuticals (Nasdaq:ZNTL)Stock Analysis - Simply Wall Street
Zentalis Pharmaceuticals stock gains after ovarian cancer trial update and insider buying - AD HOC NEWS
DarkHorse Technologies Inc. Common Shares (DRK) News Headlines - Nasdaq
William Blair Initiates Zentalis Pharmaceuticals at Outperform - Yahoo Finance
Zentalis at Wells Fargo conference: azenosertib gains clearer path - Investing.com
Zentalis Pharmaceuticals stock gains as investor conferences highlight azenosertib program - ad-hoc-news.de
Zentalis to present at Wells Fargo, Morgan Stanley events | 2026-09-02 | Investing News - stockhouse.com
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Four new hires get rights to buy 269,000 Zentalis shares - Stock Titan
Zentalis Pharmaceuticals: Data Due H1 '27 Will Clarify Prospects Of Azenosertib (ZNTL) - Seeking Alpha
Zentalis (ZNTL) Earnings Snapshot: EPS Does Not Reach the Reported Estimate; After Earnings: Shares Move 3.19% HigherEarnings Power Value - vinanet.vn
Zentalis (ZNTL) Q2 2026 Results: Reported EPS Misses Expectations in the Available Record; Share Move: The Stock Ends Down 1.70% in the Current UpdateReturn On Capital - vinanet.vn
Zentalis (ZNTL) Results Check: The EPS Result Is Below Expectation in the Available Record; Price Reaction: The Stock Records a 0.39% Decrease in the Available RecordEarnings Turnaround - vinanet.vn
Zentalis (ZNTL) Earnings Report: EPS Does Not Reach the Reported Estimate on the Day; Stock Move: The Share Price Adds 0.52% in the Latest ReadingFiscal Year Earnings - vinanet.vn
Zentalis Pharmaceuticals Insider Bought Shares Worth $15,172,500, According to a Recent SEC Filing - Yahoo Finance
Zentalis Pharmaceuticals(ZNTL.US) 10% Shareholder Buys US$15.17 Million in Common Stock - Moomoo
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Group Walters Buys 4,335,000 Shares of Stock - MarketBeat
Walters Group acquires $15.17 million in Zentalis Pharmaceuticals stock - Investing.com
Nearly one-fifth of Zentalis (NASDAQ: ZNTL) sits with one investor group - Stock Titan
Zentalis Pharma closes $92.6 million public offering - The Pharma Letter
Zentalis Pharmaceuticals closes $92.6 million stock offering By Investing.com - Investing.com Canada
Zentalis Pharmaceuticals closes $92.6 million stock offering By Investing.com - Investing.com South Africa
Zentalis Pharmaceuticals closes $92.6 million stock offering By Investing.com - Investing.com Nigeria
Zentalis Pharmaceuticals closes $92.6 million stock offering - Investing.com
Zentalis Pharmaceuticals closes $92.6 million stock offering By Investing.com - Investing.com India
Zentalis Pharmaceuticals closes $92.6 million stock offering By Investing.com - Investing.com UK
Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Zentalis Pharmaceuticals Announces Closing of Underwritten - GlobeNewswire
GSA Capital Partners LLP Buys New Shares in Zentalis Pharmaceuticals, Inc. $ZNTL - MarketBeat
Zentalis Pharmaceuticals Closes Offering of Common Shares - Yahoo Finance
Zentalis prices $80.5M stock offering to fund ovarian cancer drug - Dealroom
Zentalis raises $92.6M for trials, filings and what follows - Stock Titan
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Zentalis Pharmaceuticals Shares Fall After Pricing $80.5 Million Offering to Fund Clinical Pipeline - marketscreener.com
Finanzdaten der Zentalis Pharmaceuticals Inc-Aktie (ZNTL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Zentalis Pharmaceuticals Inc-Aktie (ZNTL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Vultaggio Vincent | PAO and PFO |
Feb 10 '26 |
Sale |
2.42 |
6,894 |
16,699 |
146,506 |
| Vultaggio Vincent | PAO and PFO |
Feb 09 '26 |
Sale |
2.39 |
3,379 |
8,086 |
153,400 |
| Bruns Ingmar | Chief Medical Officer |
Feb 09 '26 |
Sale |
2.39 |
335 |
802 |
33,332 |
| EASTLAND JULIA MARIE | CEO & President |
Feb 09 '26 |
Sale |
2.39 |
889 |
2,127 |
79,133 |
| Vultaggio Vincent | PAO and PFO |
Feb 06 '26 |
Sale |
2.43 |
29,951 |
72,772 |
156,779 |
| Bruns Ingmar | Chief Medical Officer |
Feb 06 '26 |
Sale |
2.43 |
2,962 |
7,197 |
33,667 |
| EASTLAND JULIA MARIE | CEO & President |
Feb 06 '26 |
Sale |
2.43 |
7,866 |
19,112 |
80,022 |
| Vultaggio Vincent | PAO and PFO |
Feb 03 '26 |
Sale |
2.52 |
556 |
1,398 |
186,730 |
| Vultaggio Vincent | PAO and PFO |
Feb 02 '26 |
Sale |
2.55 |
2,540 |
6,477 |
187,286 |
| WALTERS GROUP | 10% Owner |
Dec 31 '25 |
Buy |
1.20 |
6,459,973 |
7,751,968 |
13,509,973 |
6.71%
0.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):